Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness

Tania Gamberi , Giovanni Chiappetta (1) , Tania Fiaschi , Alessandra Modesti , Flavia Sorbi , Francesca Magherini

1 SMBP - Spectrométrie de Masse Biologique et Protéomique (USR3149 / FRE2032)

Auranofin is an oral gold(I) compound, initially developed for the treatment of rheumatoid arthritis. Currently, Auranofin is under investigation for oncological application within a drug repurposing plan due to the relevant antineoplastic activity observed both in vitro and in vivo tumor models. In this review, we analysed studies in which Auranofin was used as a single drug or in combination with other molecules to enhance their anticancer activity or to overcome chemoresistance. The analysis of different targets/pathways affected by this drug in different cancer types has allowed us to highlight several Med Res Rev.

Mots clés: 17AAG; 17-Allylamino-17-demethoxygeldanamycin; 2-DG; 2-deoxy-D-glucose; 5-FU; 5-fluorouracil; AAL; acute lymphoblastic leukemia; ADE; adenanthin; AF; auranofin; AKT; serine/threonine kinase 1; ANXA5; annexin A5; APL; acute Promyelocytic Leukemia; ATRA; all-trans-retinoic acid

Domaines: Sciences du Vivant [q-bio]

Tania Gamberi, Giovanni Chiappetta, Tania Fiaschi, Alessandra Modesti, Flavia Sorbi, et al.. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness. Medicinal Research Reviews, 2021, ⟨10.1002/med.21872⟩. ⟨hal-03461453⟩